HomeMembersCommittees ▶ Committee

Drug/Device Discovery and Development Committee

Chair Timothy R. Watkins, MD, MSc Seattle, WA
Vice Chair Gregory B. Diette, MD Baltimore, MD
Committee Member Alan H. Cohen, MD Menlo Park, CA
Committee Member Craig S. Conoscenti, MD, ATSF Ridgefield, CT
Committee Member Courtney Crim, MD Raleigh, NC
Committee Member Joshua P. Fessel, MD, PhD Nashville, TN
Committee Member Mark S. Forshag, MHA, MD New Orleans, LA
Committee Member C. Matthew Kinsey, MD, MPH South Burlington, VT
Committee Member Jason P. Kirkness, PhD Irvine, CA
Committee Member Heidi M. Mansour, PhD, RPh Tucson, AZ
Committee Member Joel Moss, MD, PhD, ATSF Bethesda, MD
Committee Member - PAR Representative Gregory R. Porta Mason, OH
Committee Member S.Vamsee Raju Birmingham, AL
Committee Member Colin Reisner, MD, FCCP Morristown, NJ
Committee Member Paul J. Rowe, MD Jersey City, NJ
Committee Member Marcella K. Ruddy, MD Tarrytown, NY
Committee Member Theodore J. Witek, DrPH, ATSF Burlington, ON, Canada
Staff Vlada K. O'Hara New York, NY
Staff Michelle Turenne New York, NY
Staff Lara Endreszl New York, NY

This committee provides a forum within the Society where members may discuss the basic, translational and clinical science surrounding the discovery and development of new drugs and devices, regardless of genesis or financial support. Additionally, the committee will serve as an ad hoc resource to the ATS Committee on Ethics and Conflict of Interest and the ATS Education Committee. It will provide the Society with the strategies and specific methods to distribute knowledge, which relates to the art and principles of translational research to its members. The goal is to enhance collaboration among all scientists.

Benchmarks, 2017-2018:
Translational Core Curriculum
a. Develop and implement a Respiratory Innovation Summit for 2018;
b. Identify gaps and future ATS-driven opportunities leading to educational programs for the next 5 years;
c. Collaborate with the Training Committee and others (MITT, assemblies) to further develop the Research Core Training Program, launching in 2018;
d. Evolve the Bear Cage and ensure broader visibility and marketing;
e. Develop and obtain acceptance of an “Innovation Forum” section for recurring publication in one of the ATS journals, specific to innovative advancements in therapeutics, devices and other public health/policy issues relevant to the ATS community;
f. Ensure translational core curriculum objectives are organized in a manner that enhances inclusion and collaboration between industry, university and governmental members of the ATS, large pharma and biotech sectors.

Membership and Career Development
a. Continue collaboration with MITT, Training committee and others to ensure that engagement with junior members evolves to create greater knowledge and awareness of innovation, entrepreneurship and translational sciences as well as career opportunities in industry.
b. Continue to work with the membership committee and other senior ATS leaders to engage existing members and recruit new members from the biopharma industry and other capital investment groups to ATS membership, promoting the goal of advancing health in respiratory disease, critical illness, and sleep disorders.
c. Engage early career professionals in the awards process through committee membership and participation.